1
/
의
1
Elabscience
SKU(재고 관리 코드):PKSH033618
Recombinant Human IFN-λ3/IL-28B Protein
Recombinant Human IFN-λ3/IL-28B Protein
Introducing the Recombinant Human IFN-Λ3/IL-28B Protein, a cutting-edge biotechnological advancement in the field of immunology. This highly purified protein is meticulously engineered using state-of-the-art recombinant DNA technology, ensuring its utmost quality and efficacy.
The Recombinant Human IFN-Λ3/IL-28B Protein is derived from human cells, making it biologically identical to the naturally occurring protein. This remarkable similarity allows for seamless integration into the body's immune system, facilitating enhanced immune responses against viral infections and other immunological challenges.
With its potent antiviral properties, this protein acts as a powerful defense mechanism against a wide range of viral pathogens. By stimulating the immune system, it promotes the production of antiviral proteins, inhibiting viral replication and effectively combating viral infections.
Furthermore, the Recombinant Human IFN-Λ3/IL-28B Protein exhibits exceptional immunomodulatory effects, regulating the immune response to maintain a delicate balance between inflammation and immune activation. This feature is particularly beneficial in autoimmune disorders, where it helps alleviate symptoms and restore immune homeostasis.
Our product undergoes rigorous quality control measures to ensure its purity, potency, and safety. It is manufactured in compliance with the highest industry standards, adhering to Good Manufacturing Practices (GMP) guidelines.
The Recombinant Human IFN-Λ3/IL-28B Protein is supplied in a lyophilized form, preserving its stability and extending its shelf life. It can be easily reconstituted with a suitable solvent, allowing for convenient and efficient usage in various research applications, including in vitro studies, preclinical investigations, and therapeutic development.
In summary, the Recombinant Human IFN-Λ3/IL-28B Protein represents a breakthrough in immunological research and therapeutic interventions. Its exceptional purity, potency, and immunomodulatory properties make it an invaluable tool for scientists, clinicians, and researchers alike, paving the way for advancements in the field of immunotherapy and antiviral treatments.
The Recombinant Human IFN-Λ3/IL-28B Protein is derived from human cells, making it biologically identical to the naturally occurring protein. This remarkable similarity allows for seamless integration into the body's immune system, facilitating enhanced immune responses against viral infections and other immunological challenges.
With its potent antiviral properties, this protein acts as a powerful defense mechanism against a wide range of viral pathogens. By stimulating the immune system, it promotes the production of antiviral proteins, inhibiting viral replication and effectively combating viral infections.
Furthermore, the Recombinant Human IFN-Λ3/IL-28B Protein exhibits exceptional immunomodulatory effects, regulating the immune response to maintain a delicate balance between inflammation and immune activation. This feature is particularly beneficial in autoimmune disorders, where it helps alleviate symptoms and restore immune homeostasis.
Our product undergoes rigorous quality control measures to ensure its purity, potency, and safety. It is manufactured in compliance with the highest industry standards, adhering to Good Manufacturing Practices (GMP) guidelines.
The Recombinant Human IFN-Λ3/IL-28B Protein is supplied in a lyophilized form, preserving its stability and extending its shelf life. It can be easily reconstituted with a suitable solvent, allowing for convenient and efficient usage in various research applications, including in vitro studies, preclinical investigations, and therapeutic development.
In summary, the Recombinant Human IFN-Λ3/IL-28B Protein represents a breakthrough in immunological research and therapeutic interventions. Its exceptional purity, potency, and immunomodulatory properties make it an invaluable tool for scientists, clinicians, and researchers alike, paving the way for advancements in the field of immunotherapy and antiviral treatments.
Share
